- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06111183
Evaluation of AUP12602-C as New Topical Treatment for DFUs (DIAMEND STUDY)
October 30, 2023 updated by: Aurealis Oy
Phase-2, Multi-centre, Prospective, Randomized, Standard-of-care Plus Placebo-controlled, Patient and Central Evaluator Blinded, Parallel Arm, Clinical Study to Evaluate Safety, Tolerability and Efficacy of the AUP1602-C as Treatment for Non-healing Neuro-ischemic DFU
This is a phase 2 study performed in diabetic foot ulcer (DFU) patients with chronic non-healing, neuro-ischemic wounds to investigate the safety, tolerability and efficacy of AUP1602-C.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a phase 2 multi-centre, parallel arm, patient and central evaluator-blinded, randomized, SoC plus placebo-controlled study of the RP2D of AUP1602-C performed in DFU patients with non-healing wounds.
The RP2D of AUP1602-C derived from phase 1 study is 2.5 x 10E8 CFU/cm2 ulcer area and is used in this study.
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Haritha Samaranayake, MD
- Phone Number: +358504384996
- Email: haritha@aurealistherapeutics.com
Study Locations
-
-
-
Münster, Germany
- Recruiting
- Institut für Diabetesforschung Muenster GmbH
-
Contact:
- Dirk Lammers
- Email: diabetesforschung@diabetes-muenster.de
-
Pirna, Germany
- Recruiting
- Hauärztliche und Diabetologische Praxis
-
Contact:
- Christine Kosch
- Email: info@diabetologie-pirna.de
-
-
-
-
-
Arezzo, Italy
- Not yet recruiting
- Ospedale San Donato
-
Contact:
- Alessia Scatena
-
Firenze, Italy
- Not yet recruiting
- Azienda Ospedaliero-Universitaria Careggi
-
Contact:
- Matteo Monami
-
Pisa, Italy
- Not yet recruiting
- AOU Pisana - Ospedale S. Chiara
-
Contact:
- Alberto Piaggesi
- Email: pec-aoupisana@legalmail.it
-
Pistoia, Italy
- Recruiting
- Ospedale S. Jacopo Pistoia, Diabetologia e Diabetic foot unit Aziendale
-
Contact:
- Roberto Anichini
-
-
-
-
-
Poznan, Poland
- Not yet recruiting
- Med-Polonia Sp. z o.o.
-
Contact:
- Malwina Grobelna
-
Warsaw, Poland
- Recruiting
- PODOS Klinika Leczenia Ran Podema sp. z o.o.
-
Contact:
- Marcin Malka
- Email: przychodnia@podos.pl
-
Wrocław, Poland
- Recruiting
- Lecran Centrum Opieki Nad Ranami
-
Contact:
- Konrad Pańczak
- Email: rejestracja@lecran.pl
-
Łódź, Poland
- Recruiting
- Mikomed
-
Contact:
- Jacek Mikosinski
- Email: mikomed@mikomed.pl
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female patients aged 18 and above
- Patients with DM of type 1 or 2 having a glycosylated haemoglobin (HbA1c) of ≤ 11.0% OR 97.0 mmol/mol OR 14.9 mmol/l at randomization undergoing therapy for glycaemic control using available diabetes drugs including insulin
Patients with at least one DFU that fulfils all the following criteria:
- Non-healing target ulcer defined as ≤ 20.0% reduction in area in response to SoC during the 2-weeks run-in period,
- Duration: ≥ 4 weeks and ≤ 12 months at screening visit 1,
- Located either in the plantar or on the dorsum of foot, or at or below the ankle,
- Ulcer is accessible for administration of IMP and can be completely covered by the primary and secondary dressings,
- Full-thickness, not involving bone or joints (i.e., University of Texas classification Grade 1A, 1C, 2A, 2C)(5),
- No clinical signs of active wound infection defined by IDSA/IWGDF criteria(6) or clinical evidence osteomyelitis at randomization (V1),
- Area of the target ulcer between 1.0-10.0 cm2 after debridement at randomization (V1)
- Ulcer and periwound tissue suitable for application of film dressings (i.e., no contraindications and sufficient periwound space to hold the dressing).
- Patients with more than one ulcer will be included if ulcers are separated by a minimum of 2.0 cm healthy tissue. The largest ulcer fulfilling the inclusion criteria will be selected for the investigational treatment.
- Patients with either an ankle brachial index (ABI) ≥ 0.7 OR a toe-brachial index (TBI) ≥ 0.5, AND a toe systolic pressure of at least 50.0 mmHg (or ankle systolic pressure of at least 70.0 mmHg if toe-pressure is not measured) on the foot with the target ulcer.
- Revascularized patients with an ulcer fulfilling the inclusion criteria can be included 3.0 months after the procedure.
- Patients with an assessment of the baseline level of neuropathy in the lower limb where the target ulcer is located.
- Patients must be willing to wear off-loading footwear, while ambulating, for the period requested by the Investigator.
- A woman of childbearing potential (WOCBP) must have a negative serum pregnancy test at the time of screening after sign the informed consent and a negative pregnancy dip-stick test at baseline (before starting treatment).
- Females of childbearing potential must agree to use a highly effective contraceptive measure (methods that can achieve a failure rate of less than 1% per year when used consistently and correctly) , throughout the study. / Male patients who are biologically capable of having children must agree to apply at least two methods of contraception including male barrier protection throughout the study.
- Patients who understand and are willing to comply with study procedures and give written informed consent prior to enrolment in the study or initiation of study procedures.
Exclusion Criteria:
- Participating in another clinical study or treatment with another investigational product and/or medical device in the 30 days prior to inclusion in the study or within the 5 half-lives of the investigational product, whichever is longer.
- Current or previous (within 30 days prior to start of run-in period) treatment of target ulcer with a treatment that could interfere with wound healing/IMP such as biological agents, growth factors, skin equivalents/substitutes (e.g., Regranex®, Apligraf®, or Dermagraft®), keratinocytes, platelet-rich-plasma, collagen products, blood products, placental products, oxygen therapy, topical steroids.
- Current or previous (within 1 week prior to first IMP (AUP1602-C or placebo) dosing) treatment with active wound care agents (e.g., local/topical antibiotics OR antibacterials such as silver, iodine, chlorhexidine) OR systemic antibiotics for any indication.
- Current or previous (within 2 weeks prior to first IMP (AUP1602-C or placebo) dosing) use of corticosteroids and immunosuppressants. Treatment with immunosuppressive agents with known therapeutic effects longer than 2 weeks may be considered as exclusion and should be consulted with Medical Monitor/Sponsor.
- Known hypersensitivity to any of the components of AUP1602-C or placebo
- Ulcer of University of Texas Grade ≥ 3, with deep abscess, sinus track, necrosis or gangrene that cannot be removed by debridement.
- Target ulcers with excessive exudation requiring more than one dressing change within 24-hrs.
- Target ulcers with clinically significant periwound skin maceration.
- Target ulcer with known or suspected active infection, which requires antimicrobials. Any antibiotic therapy must be completed or discontinued within 1 week prior to first IMP (AUP1602-C or placebo) dosing.
- Target ulcers requiring urgent vascular surgical interventions.
- Target ulcer other than non-healing DFU fulfilling inclusion criteria (e.g., including, but not limited to, pressure ulcers, burn wounds).
- Serum creatinine level of > 3.0 times the upper limit of normal (ULN).
- Prior radiation therapy (within 6 weeks prior to first IMP (AUP1602-C or placebo) dosing) of any part of the foot/leg bearing the target ulcer under study or total body irradiation.
- Sickle-cell diseases, Reynaud's, or other peripheral vascular disease including venous leg ulcers or any vasculitic ulcer irrespective of the cause will be excluded.
- Active or unstable Charcot deformity of the study foot (i.e., foot is erythematous, warm, oedematous, and is actively remodelling).
- Patients with other reasons for wound healing disturbances: e.g., bleeding disorders, vitamin K deficiency, hypocalcaemia, major immune deficiencies.
- Active malignant disease of any kind except for basal cell carcinoma (of the skin) not co-located with the target ulcer. A patient, who has had a malignant disease in the past, completed treatment and is currently disease-free and not on active treatment for at least 3 months, may be considered for study entry. Cancer therapies with known therapeutic effects longer than 3 months may be considered as exclusion and should be consulted with Medical Monitor/Sponsor.
- Haemoglobin of less than 8.5 g/dL
- Liver transaminase & total bilirubin levels greater than 3 times ULN.
- Patients receiving haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) therapy.
- Positive for hepatitis B or C virus (HBV, HCV), or human immunodeficiency virus (HIV) (serology test results up to 3 months prior signing ICF accepted).
- Patients with confirmed active infection with SARS-CoV-2 and related disease (COVID-19) at Baseline (V1) prior to first administration of trial medication.
- Planned major surgery during the run-in, treatment and post-treatment efficacy and safety follow-up period of the study.
- Known abuse of alcohol, drugs, or medical products. Tobacco use will be allowed.
- Previous treatment with AUP1602-C.
- Any diagnosed unstable psychological or physical condition including major organ failure that could interfere with compliance.
- Myocardial infarction diagnosed within 1 month prior to start of run-in period.
- White Blood Cells (WBC) < 3.0 X 109 cells/L;> 12.0 X 109 cells/L
- Albumin < 2.5 g/dL (or total protein < 4.0 g/dl).
- The patient has any other factor/reason which may, in the opinion of the Investigator, compromise participation and/or follow-up in the study.
- Pregnant or lactating woman at the time of signing the informed consent and prior to first IMP (AUP1602-C or placebo) dosing.
- Close affiliation with the Investigator (e.g., a close relative, financially dependent on the investigational site) or patient who is an employee of the Sponsor's company.
- Patients who are institutionalized because of legal or regulatory order.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AUP1602-C
AUP1602-C is administered topically during the treatment period.
|
AUP1602-C is topically applied on chronic wounds and covered by wound dressing.
|
Placebo Comparator: Placebo
Placebo is administered topically during the treatment period.
|
Placebo is topically applied on chronic wounds and covered by wound dressing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of local and systematic adverse events (AEs)
Time Frame: 6 weeks
|
Incidence of local and systematic adverse events (AEs) for repeatedly administered AUP1602-C and of the placebo control arm.
|
6 weeks
|
Incidence of Wound Closure
Time Frame: 20 weeks
|
Proportion of patients with a target ulcer achieving complete wound closure
|
20 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the effect size of the efficacy parameters for AUP1602-C and placebo control arm in DFU patients
Time Frame: 20 weeks
|
|
20 weeks
|
To evaluate the effect size of the efficacy parameters for AUP1602-C and placebo control arm in DFU patients
Time Frame: 20 weeks
|
|
20 weeks
|
To evaluate the effect size of the efficacy parameters for AUP1602-C and placebo control arm in DFU patients
Time Frame: 20 weeks
|
|
20 weeks
|
To evaluate the effect of the RP2D and selected treatment schedules on the percentage of wound area reduction in DFU patients
Time Frame: 20 weeks
|
• Percentage of wound area reduction
|
20 weeks
|
To evaluate the effect of the RP2D and selected treatment schedules on the percentage of wound area reduction in DFU patients
Time Frame: 20 weeks
|
|
20 weeks
|
To evaluate the effect of the RP2D and selected treatment schedules on the percentage of wound area reduction in DFU patients
Time Frame: 20 weeks
|
|
20 weeks
|
To evaluate the effect of the RP2D and selected treatment schedules long-term healing in DFU patients
Time Frame: 20 weeks
|
• Proportion of patients with complete wound closure
|
20 weeks
|
To evaluate the effect of the RP2D and selected treatment schedules ulcer recurrence in DFU patients
Time Frame: 20 weeks
|
• Proportion of patients with a target ulcer recurrence
|
20 weeks
|
Changes in Quality of Life according to EQ-5D-5L
Time Frame: 20 weeks
|
Change from baseline in health-related quality is assessed according to EuroQoL-5 Dimensions (EQ-5D-5L) patient quesionnaire.
Five single-item dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) are assessed.
Result of the questionnaire is scored from 0 (worst health imaginable) to 100 (best health imaginable).
|
20 weeks
|
Changes in Quality of Life according to DLQI
Time Frame: 20 weeks
|
Change from baseline in health-related quality is assessed according to Dermatology Life Quality Index (DLQI).
It consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected).
The DLQI score will be calculated as the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.
|
20 weeks
|
Changes in pain assessment according to VAS
Time Frame: 20 weeks
|
Change from baseline in patient's pain intensity according to a numerical Visual Analog Scale (VAS) ranging from 0 = no pain to 10= worst imaginable pain.
|
20 weeks
|
Incidence of target ulcer related hospital visits
Time Frame: 20 weeks
|
|
20 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 21, 2023
Primary Completion (Estimated)
October 31, 2025
Study Completion (Estimated)
October 31, 2025
Study Registration Dates
First Submitted
October 9, 2023
First Submitted That Met QC Criteria
October 30, 2023
First Posted (Actual)
November 1, 2023
Study Record Updates
Last Update Posted (Actual)
November 1, 2023
Last Update Submitted That Met QC Criteria
October 30, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AT-W-CLI-2022-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcer
-
University of MinnesotaRecruitingDiabetes Mellitus | Foot Ulcer | Ulcer | Diabetic Foot Ulcer | Foot Ulcer, Diabetic | Ulcer Foot | Ulcer, Leg | Ankle UlcerUnited States
-
Community Pharmacology Services LtdKeneric HealthcareNot yet recruitingDiabetic Foot Ulcer | Diabetic Foot Ulcer Neuropathic | Diabetic Foot Ulcer Ischemic
-
University of PadovaUnknownDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Deformities FootItaly
-
Johns Hopkins UniversityWithdrawnDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Mixed | Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot)
-
Corporacion Parc TauliCompletedDiabetic Foot Ulcer | Diabetic Foot Ulcer NeuropathicPakistan
-
Exciton Technologies Inc.CompletedDiabetic Foot Ulcer | Diabetic Foot Infection | Non-healing Diabetic Foot UlcerCanada
-
Baylor College of MedicineLifeNet HealthCompletedDiabetic Foot Ulcer | Deep Diabetic Foot UlcerUnited States
-
National and Kapodistrian University of AthensTerminatedDiabetic Foot | Chronic Diabetic Foot Ulcer of Right Foot | Neuropathic Foot Ulcer | Chronic Diabetic Ulcer of Left Foot (Diagnosis)Greece
-
ETS Wound Care, LLCProfessional Education and Research InstituteCompletedDiabetic Foot | Diabetic Foot Ulcer | Ulcer FootUnited States
-
University of the PunjabHigher Education Commission (Pakistan); Centre of Excellence in Molecular Biology... and other collaboratorsRecruitingDiabetes Mellitus | Diabetic Foot | Foot Ulcer | Diabetes Complications | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Foot Ulcer Due to Type 1 Diabetes Mellitus | Foot Ulcer Due to Type 2 Diabetes Mellitus | Chronic Diabetic Ulcer of Left Foot | Chronic Diabetic Foot...Pakistan
Clinical Trials on AUP1602-C
-
Aurealis OyCompleted
-
IlDong Pharmaceutical Co LtdCompleted
-
International Centre for Diarrhoeal Disease Research...University of California, DavisCompletedMalnourished Children
-
University of MiamiRecruitingHypoplastic Left Heart SyndromeUnited States
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedAdvanced CancerUnited Kingdom
-
Direction Centrale du Service de Santé des ArméesRecruitingEating Habit | Cold Exposure | HeatFrance
-
Kolon Life ScienceCompletedDegenerative ArthritisKorea, Republic of
-
U.S. Army Medical Research and Development CommandPPD; Idorsia Pharmaceuticals Ltd.; Berry Consultants; Cambridge Cognition Ltd; Ci...RecruitingPost Traumatic Stress DisorderUnited States
-
Massachusetts General HospitalNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingAnxiety | MTBI - Mild Traumatic Brain InjuryUnited States